公开(公告)号：WO2021118924A2

公开(公告)日：2021-06-17

申请号：PCT/US2020/063595

申请日：2020-12-07

申请人： TING THERAPEUTICS LLC

发明人： ZUO, Jian ,  TEITZ, Tal

IPC分类号： C07K14/71 ,  C07K14/485 ,  C12N15/113 ,  A61P27/16 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06

摘要： Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.

公开(公告)号：WO2022051029A2

公开(公告)日：2022-03-10

申请号：PCT/US2021/041197

申请日：2021-07-10

申请人： TING THERAPEUTICS LLC

发明人： ZUO, Jian ,  LI, Zhuo ,  FLEEGEL, Jonathan ,  ZALLOCCHI, Marisa, Laura

IPC分类号： A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/165 ,  A61K31/22 ,  A61K31/397 ,  A61K31/609 ,  A61K33/24

摘要： In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. Momelotinib and Fedratinib exhibit excellent protection against antibiotic-induced hearing loss in zebrafish and mice when administered prophylactically. In one aspect, Momelotinib or Fedratinib can be used as a therapy for the treatment and/or prevention of hearing loss. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：WO2022011325A8

公开(公告)日：2022-01-13

申请号：PCT/US2021/041199

申请日：2021-07-10

申请人： TING THERAPEUTICS LLC

发明人： ZUO, Jian ,  DERMANAKI, Pezhman, Salehi ,  ZALLOCCHI, Marisa, Laura ,  VIJAYAKUMAR, Sarath

IPC分类号： A61K31/167 ,  A61K31/4035 ,  A61K45/06 ,  A61K31/165 ,  A61K31/22 ,  A61K31/397 ,  A61K31/609 ,  A61K33/24

摘要： Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and Cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of Cisplatin- or noise- induced hearing loss. In one aspect, use of Niclosamide, Ingenol, and Elesclomol as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：WO2022011325A1

公开(公告)日：2022-01-13

申请号：PCT/US2021/041199

申请日：2021-07-10

申请人： TING THERAPEUTICS LLC

发明人： ZUO, Jian ,  DERMANAKI, Pezhman, Salehi ,  ZALLOCCHI, Zarisa, Laura ,  VIJAYKUMAR, Sarath

IPC分类号： A61K31/167 ,  A61K31/4035 ,  A61K45/06

摘要： Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and Cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of Cisplatin- or noise- induced hearing loss. In one aspect, use of Niclosamide, Ingenol, and Elesclomol as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：WO2022020114A2

公开(公告)日：2022-01-27

申请号：PCT/US2021/041124

申请日：2021-07-09

申请人： TING THERAPEUTICS LLC

发明人： ZUO, Jian ,  VIJAYAKUMAR, Sarath ,  ZALLOCCHI, Marisa, Laura ,  DIGUISEPPI, Joseph, A.

IPC分类号： A61P27/16 ,  A61P35/00 ,  A61K38/17 ,  A61K38/55 ,  A61K31/165 ,  A61K31/22 ,  A61K31/397 ,  A61K31/609 ,  A61K33/24 ,  A61K45/06

摘要： In one aspect, use of Afatinib as an active agent to treat a hearing loss and to prevent a hearing loss, and methods of treating and/or preventing hearing losss or disorders using the compositions are disclosed. In particular, a method for treating sensorineural hearing loss, including the steps of delivering to a patient in need thereof a composition comprising a therapeutically effective amount of Afatinib, or pharmaceutically acceptable salt thereof is provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：WO2022060811A1

公开(公告)日：2022-03-24

申请号：PCT/US2021/050425

申请日：2021-09-15

申请人： TING THERAPEUTICS LLC

发明人： ZUO, Jian ,  ZALLOCCHI, Marisa, Laura ,  HATI, Santanu ,  NORTH, Jeff

IPC分类号： C07D211/86 ,  C07D223/10 ,  C07D401/04

摘要： In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-S,6-dihydropyridin-2(1H)-one and derivatives exhibit excellent protection against antibiotic-induced hearing loss in zebrafish and mice. In one aspect, (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-S,6-dihydropyridin-2(1H)-one and derivatives can be used as a therapy for the treatment and/or prevention of hearing loss. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.